Text size A A

News

Date Title and Summary Additional Formats
Toggle Summary AGTC Added to NASDAQ Biotechnology Index
GAINESVILLE, Fla., and CAMBRIDGE, Mass., Dec. 15, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, today announced
View HTML
Toggle Summary AGTC and 4D Molecular Therapeutics Sign Collaboration Agreement for Gene Therapy Vector Discovery and Product Development
Industry Leaders in Gene Therapy Vector Discovery to Create and Develop Products for Treating Severe Ophthalmic Diseases
View HTML
Toggle Summary AGTC and BCM Families Foundation Announce Collaboration to Develop AAV-Based Gene Therapy for Blue Cone Monochromacy
GAINESVILLE, Fla. and JUPITER, Fla. and CAMBRIDGE, Mass. , Jan. 06, 2016 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases,
View HTML
Toggle Summary AGTC and Bionic Sight Announce Strategic Collaboration to Develop an Optogenetic Therapy and Device for Visual Deficits and Blindness
Innovative approach will combine AGTC's gene therapy expertise with Bionic Sight's neuro-prosthetic device to potentially restore retinal function
View HTML
Toggle Summary AGTC and Collaborators Present New Data on the Natural History of X-Linked Retinoschisis (XLRS) at the Association for Research in Vision and Ophthalmology (ARVO) Annual Meeting
Results expected to enhance development of AGTC's XLRS gene therapy candidate; Phase 1/2 clinical trial currently enrolling patients at multiple locations across the United States
View HTML
Toggle Summary AGTC and Icagen Announce Technology Transfer Agreement
AGTC and Icagen Announce Technology Transfer Agreement June 24, 2010 – AGTC, a privately held company, and Icagen, Inc. (NASDAQ: ICGN) today announced the completion of an agreement for the purchase and sale of certain patent rights between the companies.  Icagen is transferring its rights to
View HTML
Toggle Summary AGTC and JDRF announce partnership to develop gene therapy for diabetic eye disease
AGTC and JDRF announce partnership to develop gene therapy for diabetic eye disease May 16, 2006 – The Juvenile Diabetes Research Foundation has joined in a partnership with AGTC (Applied Genetic Technologies Corp.) and Genzyme Corporation to develop a gene therapy treatment to potentially prevent
View HTML
Toggle Summary AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases
AGTC and National Neurovision Research Institute Collaborate, Funding Research in two Genetic Retinal Diseases Combined Funds and Resources to be used to further demonstrate the AGTC’s AAV system’s ability to deliver sustainable treatments for human retinal diseases.
View HTML
Toggle Summary AGTC and SAFC Create Strategic Partnership to Provide Gene Therapy Manufacturing Services
GAINESVILLE, Fla. and CARLSBAD, Calif., June 24, 2014 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a clinical stage biotechnology company developing adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye diseases, and SAFC Commercial (SAFC),
View HTML
Toggle Summary AGTC and Synpromics Limited Announce R&D Collaboration to Develop Synthetic Promoters for Enhanced Gene Therapy Candidates
GAINESVILLE, Fla. , CAMBRIDGE, Mass. and EDINBURGH, Scotland , Dec. 9, 2015 (GLOBE NEWSWIRE) -- Applied Genetic Technologies Corporation (Nasdaq:AGTC), a biotechnology company conducting human clinical trials of adeno-associated virus (AAV)-based gene therapies for the treatment of rare eye
View HTML
Visionary science for life changing cures.